Please login to the form below
BI
This page shows the latest BI news and features for those working in and with pharma, biotech and healthcare.
Boehringer bolts on another immuno-oncology company
Acquires ViraTherapeutics in a €210m takeover deal
Latest news
-
GSK two-drug trial in untreated HIV raises Gilead rivalry
Another programme is pairing long-acting integrase inhibitor cabotegravir and rilpivirine and could be given as a monthly or bi-monthly injection, as an alternative to daily doses of tablets.
-
Boehringer beefs up biologics capacity with €230m investment
CD40 antibody BI 655064 in phase II for lupus nephritis. ... Following after in earlier-stage development are a first-in-class IL-36 receptor inhibitor BI 655130 for pustular psoriasis and other immune diseases, and an array of vaccines, oncoytic viruses
-
Boehringer beefs up biologics capacity with €230m investment
CD40 antibody BI 655064, in phase II for lupus nephritis. ... Following after in earlier-stage development are a first-in-class IL-36 receptor inhibitor BI 655130 for pustular psoriasis and other immune diseases, and an array of vaccines, oncoytic
-
Immuno-oncology at ASCO: survival data, combinations and new indications
Also on the agenda are preliminary clinical results with M7824, an investigational TGF‑ beta trap/anti-PD-L1 bi-functional immunotherapy fusion protein in human papillomavirus (HPV)-associated cancers and
-
Another Alzheimer's bust as Merck & Co stops verubecestat study
Since the start of the year, Boehringer Ingelheim has stopped development of its PDE9a inhibitor BI 4093906, Takeda and Zinfandel abandoned efforts to repurpose diabetes drug pioglitazone for the disease, and
More from news
Approximately 5 fully matching, plus 87 partially matching documents found.
Latest Intelligence
-
The ‘Million Hour Challenge’
Since the initiative launched, AstraZeneca has seen two consecutive increases in the bi-annual employee engagement survey, with 69% of AstraZeneca employees agreeing that ‘Together, we are making progress in our
-
Is it time we stopped talking about adherence?
attractive and valuable bi-product.
-
Deal Watch September 2016
Boehringer Ingelheim granted Amgen worldwide rights to BI 836909, a bispecific T cell engager designed to treat multiple myeloma. ... Under the agreement, Daiichi Sankyo will acquire a licence to Zymeworks' platforms to develop a bi-specific antibody
-
The human perspective
But you can deal with the other three factors. This is where Boehringer has a key strength because there is a very, very strong culture, which is built on our BI
-
Deal Watch April 2016
1, 200. ZymeWorks (US). GSK (UK). License and option. Preclinical bi-specific antibodies based on Azymetric platform for treatment of solid tumours.
More from intelligence
Approximately 0 fully matching, plus 22 partially matching documents found.
Latest from PMHub
-
Infographic: HIV Market Snapshot
Therapy Watch HIV patient data is collected bi-monthly from a panel of 150 physicians across the main 5 EU markets and 100 physicians in the US.
-
Box Bear Ltd
Box Bear Ltd. A boutique agency punching above its weight. Prefered suppliers of GSK, Roche, Shire and BI to name a few, working directly or with partners to deliver animation, video,
-
Frontera
Gold - Caphosol sales aid - Sales aid. Gold - BI interactive video - Interactive communications.
-
Frontera
Gold - Caphosol sales aid - Sales aid. Gold - BI interactive video - Interactive communications.
-
PharmiWeb Solutions Support Cancer Charity
This inaugural PharmiWeb Solutions “ Bake a Smile” event raised £200.00 on the day, with bi-weekly events already in the diary throughout the rest of 2014, and with Christopher’ s
More from PMHub
Approximately 1 fully matching, plus 9 partially matching documents found.
Featured jobs
- Account Manager, Healthcare Communications
-
£32, 000 - £40, 000 benefits
-
Scientific Team Lead
-
Competitive Salary
- Senior/ Market Access Consultant, UK, HOME BASED, £50-60K
-
Excellent package
-
Associate Medical Director
-
Highly Competitive
-
SENIOR MEDICAL WRITER IN ONCOLOGY
-
Up to £60, 000.00 pension bonus
-
Associate Medical Director
-
Salary TBC
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
-
Scientific Director
-
Highly Competitive Salary &Benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Director – Global Healthcare PR
-
Salary TBC
- Director Healthcare PR Communications
-
Salary TBC
- Experienced Editor, London, Medical Communications
-
Competitive package
-
Account Director
-
Negotiable
-
Account Director - Digital
-
Great salary and benefits
- Account Manager, Healthcare Advertising
-
Salary TBC
- Senior Account Manager / Account Director - Med Comms
-
Great salary and benefits
- Lead Medical Copywriter, Healthcare Brand Communications, London
-
Excellent package
Subscribe to our email news alerts
- The NHS in 2022: how pharma can contribute to new models of care
- Genomics England chooses Congenica for diagnostic decision support
- Ocrevus surge keeps Roche smiling in Q3
- First Humira biosimilars reach EU market
- Making Europe a leader in bioscience: boosting trust and opening minds
- Joint working that works
PMHub
EY Life Sciences
Our global reach Against a backdrop of regulatory, digital, financial and global transformation, Life Sciences companies are finding integration and...
Latest intelligence
- Making Europe a leader in bioscience: boosting trust and opening minds
- A vision of Paris as Europe’s leading hub for life sciences innovation...
- Tackling a formidable foe
- Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
- Cancer care – the power of new technologies
- With patient numbers set to soar, how can we make a difference?...
Quick links
Infographics
